Modulation of Acetylation in the Treatment of Lethal Hemorrhagic Shock

乙酰化的调节在致死性失血性休克的治疗中

• 批准号: 8053407
• 负责人: HASAN B ALAM
• 金额: $ 32.31万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-15 至 2013-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8053407
• 关键词: Acetylation; Attenuated; Cause of Death; Cell physiology; Cells; Dose; Epigenetic Process; Gene Expression; Genes; Genetic Transcription; Goals; Health; Hemorrhage; Hemorrhagic Shock; Histone Acetylation; Histone Deacetylase Inhibitor; Histones; Liquid substance; Lysine; Methods; Nuclear; Organ; Outcome; Pathway interactions; Play; Protein Acetylation; Proteins; Regulation; Regulator Genes; Research; Resuscitation; Role; Time; Translating; Trauma; cell injury; clinical practice; combat; improved; novel strategies; protective effect; treatment strategy

DESCRIPTION (provided by applicant): Hemorrhage is the leading cause of death in civilian and combat trauma, and effective resuscitation strategies have the potential of saving many lives. However, conventional resuscitation can exacerbate cellular injury caused by hemorrhagic shock. At a sub-cellular level, hemorrhagic shock and resuscitation can alter gene expression, and impair the regulation of subsequent downstream survival pathways. Nuclear histone proteins are known regulators of gene transcription, and we have previously shown that treatment with histone deacetylase inhibitors (HDACI) enhances gene transcription through specific hyperacetylation at multiple lysine residues ("epigenetic regulation"), attenuates organ damage, and improves early survival after lethal hemorrhage. Emerging evidence also suggests that acetylation of non-histone proteins may play an equally important regulatory role in cellular processes, independent of transcription. Thus, administration of HDACI (with or without conventional fluid resuscitation) appears to be a very promising strategy for the treatment of lethal hemorrhage. However, before these exciting findings can be translated into clinical practice, the most effective HDACI treatment (e.g. agent, dose, and timing), and the precise mechanisms of action must be clearly identified. LONG TERM GOALS: Develop strategies to minimize cellular injury and improve survival after lethal hemorrhage. SPECIFIC AIM 1: Identify the histone deacetylase inhibitor (HDACI) treatment that induces the most pronounced acetylation, when given after lethal non-resuscitated hemorrhage? Sub aim 1: Identify the optimal doses of HDACI for achieving maximum protein acetylation. Sub aim 2: Determine whether protein hyperacetylation can be sustained for longer duration through repeated administration of HDACI. Sub aim 3: Determine whether combining agents from different HDACI groups can enhance protein acetylation. SPECIFIC AIM 2: Establish whether addition of HDACI to resuscitation fluids is advantageous? Sub aim 1: Ascertain whether addition of HDACI to conventional fluids attenuates markers of cellular injury and improves survival? Sub aim 2: Determine whether HDACI treatment can be combined with hypertonic fluid resuscitation to achieve synergistic effects? SPECIFIC AIM 3: Determine the dominant mechanisms that are responsible for exerting the protective effects of HDACI. Sub aim 1: Identify the genes whose transcription is altered by the acetylation of histone proteins ("epigenetic mechanisms"), and study its impact on downstream proteins. Sub aim 2: Identify whether the protective effects of HDACI are due to direct acetylation of non-histone proteins. PUBLIC HEALTH RELEVANCE: Conventional methods of treating massive blood loss have proven to be ineffective, and may even worsen the outcome. Our research has shown that survival can be dramatically improved by enhancing the essential protective mechanisms that are naturally present in the cells. The aim of our project is to refine this novel approach, and develop effective strategies for the treatment of lethal blood loss.

描述（由申请人提供）：出血是平民和战斗创伤死亡的主要原因，有效的复苏策略有可能挽救许多生命。然而，常规复苏会加剧失血性休克引起的细胞损伤。在亚细胞水平上，失血性休克和复苏可以改变基因表达，并损害随后下游生存途径的调节。核组蛋白是已知的基因转录调节因子，我们之前已经证明，组蛋白脱乙酰酶抑制剂 (HDACI) 治疗可通过多个赖氨酸残基的特异性超乙酰化（“表观遗传调节”）来增强基因转录，减轻器官损伤，并提高术后早期存活率。致命的出血。新出现的证据还表明，非组蛋白的乙酰化可能在细胞过程中发挥同样重要的调节作用，与转录无关。因此，HDACI 的施用（有或没有常规液体复苏）似乎是治疗致命性出血的一种非常有前途的策略。然而，在这些令人兴奋的发现转化为临床实践之前，必须明确确定最有效的 HDACI 治疗（例如药物、剂量和时机）以及精确的作用机制。长期目标：制定策略，最大限度地减少细胞损伤并提高致命性失血后的生存率。具体目标 1：确定在致命性非复苏性出血后给予组蛋白脱乙酰酶抑制剂 (HDACI) 治疗时，该治疗可诱导最明显的乙酰化？子目标 1：确定实现最大蛋白质乙酰化的 HDACI 最佳剂量。子目标 2：确定通过重复施用 HDACI 是否可以使蛋白质过度乙酰化持续更长时间。子目标 3：确定来自不同 HDACI 组的组合药物是否可以增强蛋白质乙酰化。具体目标 2：确定在复苏液中添加 HDACI 是否有利？子目标 1：确定在常规液体中添加 HDACI 是否会减弱细胞损伤标志物并提高生存率？子目标2：确定HDACI治疗是否可以与高渗液体复苏相结合以达到协同效应？具体目标 3：确定 HDACI 发挥保护作用的主要机制。子目标 1：识别转录因组蛋白乙酰化（“表观遗传机制”）而改变的基因，并研究其对下游蛋白质的影响。子目标 2：确定 HDACI 的保护作用是否归因于非组蛋白的直接乙酰化。公共卫生相关性：治疗大量失血的传统方法已被证明是无效的，甚至可能使结果恶化。我们的研究表明，通过增强细胞中自然存在的基本保护机制可以显着提高生存率。我们项目的目的是完善这种新方法，并制定治疗致命失血的有效策略。